What's in Guizhou Bailing Group Pharmaceutical Co Ltd's pipeline?

Guizhou Bailing Group Pharmaceutical Co Ltd has 7 drugs in our index: 4 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Guizhou Bailing Group Pharmaceutical Co Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/guizhou-bailing-group-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Guizhou Bailing Group Pharmaceutical Co Ltd — Portfolio Competitive Intelligence Brief

Guizhou Bailing Group Pharmaceutical Co Ltd pipeline: 4 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
LianHuaQingWen Granules	LianHuaQingWen Granules	marketed
Guli capsule	Guli capsule	marketed
Kesuting syrup	Kesuting syrup	marketed
Kangguzengsheng capsule	Kangguzengsheng capsule	marketed	Orthopedics / Bone Health
TNTL capsule	TNTL capsule	phase 3

Therapeutic area mix

Orthopedics / Bone Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Guizhou Bailing Group Pharmaceutical Co Ltd:

Cite this brief

Drug Landscape (2026). Guizhou Bailing Group Pharmaceutical Co Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guizhou-bailing-group-pharmaceutical-co-ltd. Accessed 2026-05-16.